Cognito Therapeutics raises $35M Series B extension

Jan 30, 2024 · Cognito Therapeutics raises $35M Series B extension. January 30, 2024. 110. Linkedin. ... The round is an extension of the Series B round the company raised $73 million in …

CouponFollow Extension

$35
OFF

Cognito Therapeutics Raises $35M Series B Extension

6 days from now

Jan 30, 2024 · Cognito Therapeutics raises $35M Series B extension. January 30, 2024. 110. Linkedin. ... The round is an extension of the Series B round the company raised $73 million in …

gsmedtech.com

$35
OFF

Cognito Nets $35 Million To Advance Alzheimer's DTx Trial

6 days from now

Jan 29, 2024 · Cognito Therapeutics has raised $35 million to advance its digital therapeutic (DTx) for Alzheimer's disease, the company's CEO Brent Vaughan told FirstWord HealthTech …

firstwordhealthtech.com

$35
OFF

Cognito Raises $35M, Launches Alzheimer’s Biomarker Study

6 days from now

Feb 1, 2024 · Cognito Therapeutics Inc. closed a $35 million extension to the series B fundraising round it started in 2023, bringing the total for the round to $108 million and the total funding to …

bioworld.com

$227
OFF

Cognito Therapeutics - Raised $227M Funding From 6 Investors

6 days from now

Oct 29, 2024 · How much funding did Cognito Therapeutics raise in its latest funding round? ... $35M. Series B. 1933273. 9803532-Mar 22, 2023. $73M. Series B. 4266949. ... (United …

tracxn.com

$35000000
OFF

Series B - Cognito Therapeutics - 2024-01-29 - Crunchbase

6 days from now

Jan 29, 2024 · Cognito Therapeutics raised $35000000 on 2024-01-29 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …

crunchbase.com

$35
OFF

Series B - Cognito Therapeutics - 2023-03-22 - Crunchbase

6 days from now

Mar 22, 2023 · VatorNews — Cognito Therapeutics raises $35M Series B extension News • Mar 26, 2023 VatorNews — Digital health news, funding round up in the prior week; March 27, 2023

crunchbase.com

$73
OFF

Cognito Collects $73M For Light-and-sound Alzheimer's Therapy

6 days from now

Mar 22, 2023 · The series B round adds $73 million to Cognito’s coffers, the startup announced Wednesday. It’ll go toward the ongoing pivotal study of the noninvasive headset, which relies …

fiercebiotech.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

6 days from now

Mar 22, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, …

businesswire.com

$35
OFF

Cognito Therapeutics - Recent News & Activity - Crunchbase

6 days from now

Jul 30, 2024 · VatorNews — Cognito Therapeutics raises $35M Series B extension . News • Jan 28, 2024. VatorNews — Cognito Therapeutics raises $35M Series B extension .

crunchbase.com

$35
OFF

Cognito Therapeutics Inc. | BioWorld

6 days from now

Jul 17, 2023 · Cognito raises $35M, launches Alzheimer’s biomarker study. Feb. 1, 2024. By Annette Boyle. No Comments. Cognito Therapeutics Inc. closed a $35 million extension to the …

bioworld.com

$35
OFF

Cognito Therapeutics Raises $35M Series B Extension

6 days from now

Medical Device News by Guided Solutions Funding Cognito Therapeutics raises $35M Series B extension

guidedsolutions.co.uk

$35
OFF

Vator On LinkedIn: Cognito Therapeutics Raises $35M Series B …

6 days from now

Cognito Therapeutics, Inc. raised a $73 million round in March of 2023 #mentalhealth #Alzheimers #clinicaltrial #funding # ... Cognito Therapeutics raises $35M Series B extension ...

linkedin.com

$73
OFF

Cognito Therapeutics Scores $73m Series B - Venture Capital Journal

6 days from now

Mar 22, 2023 · The Series B funding brings Cognito’s total financing raised since inception to $93 million The funding will advance Cognito’s study of its non-invasive neuromodulation device …

venturecapitaljournal.com

4%
OFF

Cognito Therapeutics

6 days from now

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile. Citations. View. Close. a …

cognitotx.com

FAQs about Cognito Therapeutics raises $35M Series B extension Coupon?

Does Cognito therapeutics have a series B financing?

CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. ...

Who is Cognito Therapeutics?

About Cognito Therapeutics Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. ...

Is Cognito a non-invasive neuromodulation device?

Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. ...

How does Cognito treat Alzheimer's?

The light and sound is supposed to stimulate brain activity that’s disrupted by neurodegenerative conditions, potentially helping to preserve brain structure. Get unlimited access to award-winning journalism and exclusive events. Instead of drugs, Cognito treats Alzheimer's with a headset utilizing sound and gamma frequency light. ...

Can a non-drug neuromodulation intervention help treat Alzheimer's & Cognito?

“A non-drug neuromodulation intervention has the potential to better address the complex nature of neurodegenerative diseases such as Alzheimer’s and Cognito is well-positioned to be a leader in this new paradigm,” said Helen Liang, Founder & Managing Partner, FoundersX Ventures. ...